据介绍，AK104是康方生物自主研发的潜在下一代、首创人源化IgG1四聚体双特异性抗体药物，旨在优先结合肿瘤浸润淋巴细胞而非正常外周组织淋巴细胞，以提供更好的疗效和安全性。2022年6月29日，卡度尼利单抗首次获批，用于既往接受过含铂化疗治疗失败的复发或转移性宫颈癌患者，成为首个国产双抗药物。Akeso (09926) rose nearly 4%. As of the time of publication, it has increased by 3.95%, to 63.2 Hong Kong dollars, with a turnover of 0.275 billion Hong Kong dollars.
According to the Financial Network APP, Akeso (09926) rose nearly 4%. As of the time of publication, it has increased by 3.95%, to 63.2 Hong Kong dollars, with a turnover of 0.275 billion Hong Kong dollars.
On the news front, on September 23, according to the CDE official website, Akeso initiated a Phase III clinical trial of CD30N-wellantis single-chain (AK104), evaluating AK104 compared with subligen single-chain for the consolidation treatment of locally advanced unresectable non-small cell lung cancer patients who have no disease progression after synchronous/sequential radiation and chemotherapy, in a randomized, double-blind, multicenter Phase III clinical study (Phase I). It is worth mentioning that this is the first clinical study of a CD30N-wellantis monoclonal antibody head-to-head with a PD-L1 monoclonal antibody.
According to the introduction, AK104 is Akeso's self-developed potential next-generation, first-in-class humanized IgG1 tetramer bispecific antibody drug, designed to preferentially bind to tumor-infiltrating lymphocytes rather than normal peripheral tissue lymphocytes, to provide better efficacy and safety. On June 29, 2022, CD30N-wellantis was approved for the first time, for the treatment of recurrent or metastatic cervical cancer patients who have failed platinum-based chemotherapy in the past, becoming the first domestic bispecific drug.
